Status:

COMPLETED

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis

Lead Sponsor:

Paratek Pharmaceuticals Inc

Conditions:

Acute Pyelonephritis

Eligibility:

FEMALE

18-65 years

Phase:

PHASE2

Brief Summary

The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with ac...

Detailed Description

This was a randomized (1:1:1:1:1), double-blind, double-dummy, adaptive designed, Phase 2 study. Based on review of the efficacy and microbiology data, the DMC modified the randomization algorithm, an...

Eligibility Criteria

Inclusion

  • Female participants, age 18-65 years who have signed the informed consent form
  • Must have a qualifying acute pyelonephritis
  • Participants must not be pregnant at the time of enrollment
  • Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug
  • Must be able to comply with all of the requirements of the study

Exclusion

  • Males
  • Symptoms of acute pyelonephritis present for longer 7 days prior to randomization
  • Infections that require antibacterial treatment for greater than 14 days
  • Evidence of suspected non-renal source of infections, vaginitis, or sexually transmitted infection
  • Evidence of significant immunological disease
  • Evidence of liver impairment or disease
  • Evidence of unstable cardiac disease
  • Severe renal disease or requirement for dialysis
  • Evidence of septic shock
  • Has a history of hypersensitivity or allergic reaction to any tetracycline or to levofloxacin
  • Has received an investigational drug within the past 30 days
  • Participants who are pregnant or nursing
  • Unable or unwilling to comply with the protocol requirements

Key Trial Info

Start Date :

November 19 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 24 2019

Estimated Enrollment :

201 Patients enrolled

Trial Details

Trial ID

NCT03757234

Start Date

November 19 2018

End Date

July 24 2019

Last Update

July 7 2020

Active Locations (31)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (31 locations)

1

Site 201

Tbilisi, Georgia

2

Site 202

Tbilisi, Georgia

3

Site 203

Tbilisi, Georgia

4

Site 204

Tbilisi, Georgia